NasdaqGS - Delayed Quote USD

Tourmaline Bio, Inc. (TRML)

15.68 -0.32 (-2.00%)
At close: April 26 at 4:00 PM EDT
15.25 -0.43 (-2.74%)
After hours: April 26 at 7:45 PM EDT
Key Events
Loading Chart for TRML
DELL
  • Previous Close 16.00
  • Open 16.00
  • Bid 15.65 x 100
  • Ask 15.76 x 300
  • Day's Range 15.59 - 16.33
  • 52 Week Range 9.18 - 48.31
  • Volume 358,957
  • Avg. Volume 432,304
  • Market Cap (intraday) 402.137M
  • Beta (5Y Monthly) --
  • PE Ratio (TTM) --
  • EPS (TTM) --
  • Earnings Date May 13, 2024 - May 17, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 58.33

Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The company's development pipeline comprises medicines and therapies for the atherosclerotic cardiovascular disease (ASCVD) and thyroid eye disease (TED). The company was formerly known as Tourmaline Bio, LLC and changed its name to Tourmaline Bio, Inc. in September 2022. Tourmaline Bio, Inc. was founded in 2021 and is headquartered in New York, New York.

www.tourmalinebio.com

44

Full Time Employees

December 31

Fiscal Year Ends

Recent News: TRML

Performance Overview: TRML

Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

TRML
40.11%
S&P 500
6.92%

1-Year Return

TRML
35.25%
S&P 500
25.26%

3-Year Return

TRML
--
S&P 500
20.49%

5-Year Return

TRML
--
S&P 500
20.49%

Compare To: TRML

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: TRML

Valuation Measures

Annual
As of 4/26/2024
  • Market Cap

    402.14M

  • Enterprise Value

    199.60M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    1.96

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    -4.40

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -25.87%

  • Return on Equity (ttm)

    -39.66%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -42.12M

  • Diluted EPS (ttm)

    --

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    202.95M

  • Total Debt/Equity (mrq)

    0.20%

  • Levered Free Cash Flow (ttm)

    -24.92M

Research Analysis: TRML

Analyst Price Targets

48.00
58.33 Average
15.68 Current
74.00 High
 

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell
 

Earnings

Consensus EPS
 

Company Insights: TRML

Fair Value

15.68 Current
 

Dividend Score

0 Low
TRML
Sector Avg.
100 High
 

Hiring Score

0 Low
TRML
Sector Avg.
100 High
 

Insider Sentiment Score

0 Low
TRML
Sector Avg.
100 High
 

Research Reports: TRML

  • Daily – Vickers Top Insider Picks for 12/26/2023

    The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.

     
  • Daily – Vickers Top Insider Picks for 12/22/2023

    The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.

     
  • Daily – Vickers Top Insider Picks for 12/21/2023

    The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.

     
  • Daily – Vickers Top Insider Picks for 11/29/2023

    The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.

     

People Also Watch